Clinical trialTumorTumor biopsies may help to reliably distinguish hepatocellular carcinoma (HCC) from other tumors, mostly cholangiocarcinoma as well as to identify the patient populations who most benefit from
have fallen far behind the growing therapeutic demand. The difficulties associated with the approvals of new drugs, as well as the long duration of these processes, also exacerbate the dilemma.38,39In addition, conventional trial designs cannot be used to assess the efficacy of one regimen across...
Clinical Trial SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma This first-in-human trial is designed to assess the safety, feasibility and potential activity of a single IV dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian ca...
Immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cells, and tumor vaccines are the main immunotherapies used for cholangiocarcinoma so far. Although monotherapies with ICIs and tumor vaccines have failed to benefit CCA patients, the combination of ICIs and chemotherapies/targeted...
They also found that any change inDNAthat increased the amount of catalytic subunit relative to its regulatory subunit produced the same changes in the transcriptome. Some patients, for example, had a fusion to PRKACA in the ductal cells of the liver, producing cholangiocarcinoma, or in the duct...
In February 2024,Biosyngen announced that BST02 has been grantedFast Track Designationby the U.S. Food and Drug Administration (FDA) for the treatment of all types of liver cancer, including hepatocellular carcinoma...
Application (CTA) for derazantinib has been accepted by the Center for Drug Evaluation at the China National Medical Products Administration (NMPA), enabling the initiation of a registrational clinical trial in patients with second-line intrahepatic ch...
Trial Status:Active Not Recruiting Trial Phase:Phase 2 Age:18+ Sex:All Key Eligibility Criteria Disqualifiers:Not Listed 818 Participants NeededLearn More Reduced-Dose HPV Vaccine for Women with HIV Vancouver, British Columbia There are very little data on human papillomavirus (HPV) vaccination among...
PD-1 inhibitors, when combined with anti-CD40 or anti-CD137, have shown significant synergistic effects in various cancer models, such as cholangiocarcinoma, breast cancer, and colon cancer [84,85]. Furthermore, tumor antigen-releasing treatments, such as radiotherapy and chemotherapy, have been ...
(dCCA). Each subtype has a distinct epidemiology, biology, prognosis, and strategy for clinical management. The incidence of cholangiocarcinoma, particularly iCCA, has increased globally over the past few decades. Surgical resection remains the mainstay of potentially curative treatment for all three ...